New Pipeline

PIPELINE

Screen Shot 2020-06-27 at 5.18.23 PM
Discovery
Validation/Optimization
In Vivo POC
IND Studies
Phase 1
Platform: Multiple Myeloma (CD38 Targeting)
%
Candidate: KP1237 (ARM™) + Autlogous NK cells • Program: Post Transplant

3Q2020

%
Candidate: KP1237(ARM™) • Program: Darzalex® R/R

3Q2020

%
Candidate: KP1237 (ARMTM • Program: TBD • Collaborator: GC LabCell
Platform: COVID-19 (Spike Protein Targeting)
%
Candidate: TBD • Program: COVID-19 MATETM HGM
%
Candidate: TBD • Program: COVID-19 ARMTM
%
Candidate: TBD • Program: COVID-19 ARMTM Collaborator: GC LabCell